Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations
Authors:
- 1 February 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (2) , 556-9
Abstract
The emergence of resistance to amantadine in influenza A viruses has been shown to occur rapidly during treatment as a result of single-amino-acid substitutions at position 26, 27, 30, 31, or 34 within the transmembrane domain of the matrix-(M)-2 protein. In this study, reverse genetics was used to generate and characterize recombinant influenza A (H1N1) viruses harboring L26F, V27A, A30T, S31N, G34E, and V27A/S31N mutations in the M2 gene. In plaque reduction assays, all mutations conferred amantadine resistance, with drug concentrations resulting in reduction of plaque number by 50% (IC 50 s) 154- to 3,300-fold higher than those seen for the wild type (WT). M2 mutants had no impairment in their replicative capacities in vitro on the basis of plaque size and replication kinetics experiments. In addition, all mutants were at least as virulent as the WT in experimentally infected mice, with the highest mortality rate being obtained with the recombinant harboring a double V27A/S31N mutation. These findings could help explain the frequent emergence and transmission of amantadine-resistant influenza viruses during antiviral pressure in the clinical setting.Keywords
This publication has 15 references indexed in Scilit:
- Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern AsiaNature, 2004
- High Frequency of Resistant Viruses Harboring Different Mutations in Amantadine‐Treated Children with InfluenzaThe Journal of Infectious Diseases, 2003
- Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2Journal of Clinical Microbiology, 2003
- Prolonged Excretion of Amantadine-Resistant Influenza A Virus Quasi Species after Cessation of Antiviral Therapy in an Immunocompromised PatientClinical Infectious Diseases, 2002
- Influenza A Virus Can Undergo Multiple Cycles of Replication without M2 Ion Channel ActivityJournal of Virology, 2001
- Low Incidence of Rimantadine Resistance in Field Isolates of Influenza A VirusesThe Journal of Infectious Diseases, 1999
- Prolonged Shedding of Amantadine-Resistant Influenza A Viruses by Immunodeficient Patients: Detection by Polymerase Chain Reaction-Restriction AnalysisThe Journal of Infectious Diseases, 1995
- Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A virusesVirology, 1992
- Virulence of Rimantadine-Resistant Human Influenza A (H3N2) Viruses in FerretsThe Journal of Infectious Diseases, 1991
- Effect of Rimantadine on Cytotoxic T Lymphocyte Responses and Immunity to Reinfection in Mice Infected with Influenza A VirusThe Journal of Infectious Diseases, 1990